These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

645 related items for PubMed ID: 19622615

  • 1. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
    Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R.
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
    [Abstract] [Full Text] [Related]

  • 2. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R.
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [Abstract] [Full Text] [Related]

  • 3. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A.
    Neuroendocrinology; 2006 Jan; 83(3-4):249-57. PubMed ID: 17047390
    [Abstract] [Full Text] [Related]

  • 4. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
    Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G.
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2112-8. PubMed ID: 16537687
    [Abstract] [Full Text] [Related]

  • 5. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G.
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [Abstract] [Full Text] [Related]

  • 6. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G.
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
    [Abstract] [Full Text] [Related]

  • 7. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G.
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [Abstract] [Full Text] [Related]

  • 8. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide.
    Attanasio R, Barausse M, Cozzi R.
    J Endocrinol Invest; 2001 Apr; 24(4):209-16. PubMed ID: 11383906
    [Abstract] [Full Text] [Related]

  • 9. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).
    Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G.
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4099-103. PubMed ID: 11095439
    [Abstract] [Full Text] [Related]

  • 10. Octreotide as primary therapy for acromegaly.
    Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL.
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [Abstract] [Full Text] [Related]

  • 11. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM.
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
    [Abstract] [Full Text] [Related]

  • 12. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly.
    Ayuk J, Stewart SE, Stewart PM, Sheppard MC.
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4142-6. PubMed ID: 12213862
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M, Gussoni G, Cuttica CM, Giordano G.
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [Abstract] [Full Text] [Related]

  • 14. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly.
    Tutuncu Y, Berker D, Isik S, Ozuguz U, Akbaba G, Kucukler FK, Aydin Y, Guler S.
    Pituitary; 2012 Sep; 15(3):398-404. PubMed ID: 21863263
    [Abstract] [Full Text] [Related]

  • 15. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA.
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [Abstract] [Full Text] [Related]

  • 16. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
    Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C.
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological management of acromegaly: a current perspective.
    Manjila S, Wu OC, Khan FR, Khan MM, Arafah BM, Selman WR.
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [Abstract] [Full Text] [Related]

  • 18. [Novel pharmacologic therapies in acromegaly].
    Góth M, Hubina E, Kovács L, Szabolcs I.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [Abstract] [Full Text] [Related]

  • 19. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
    Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G.
    J Clin Endocrinol Metab; 2006 Apr 12; 91(4):1397-403. PubMed ID: 16449332
    [Abstract] [Full Text] [Related]

  • 20. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A, Pasireotide C2402 Study Group.
    Lancet Diabetes Endocrinol; 2014 Nov 12; 2(11):875-84. PubMed ID: 25260838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.